Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
The Onion mounts a defense of parody in Supreme Court amicus brief
11:08pm, Tuesday, 11'th Oct 2022
WASHINGTON (AP) — The Onion has some serious things to say in defense of parody.
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
07:00am, Thursday, 08'th Sep 2022
PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthc
Trading The Top 10 Stocks From 40 Large Hedge Funds: Trading Update 9/4/2022
04:24am, Monday, 05'th Sep 2022 Seeking Alpha
A strategy selecting 10 of the 50 stocks, equally weighted, would have increased total return to 178.0%, an active return of 61.6% vs. SPY.
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
09:13am, Monday, 08'th Aug 2022 Benzinga
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Carvana Co. (NYSE: CVNA) jumped 40.1% to clo
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
07:05am, Monday, 08'th Aug 2022 Benzinga
Gainers
Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results.
Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
03:55pm, Friday, 05'th Aug 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
01:33pm, Friday, 05'th Aug 2022
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics, Inc. (FOLD) CEO Bradley Campbell on Q2 2022 Results - Earnings Call Transcript
03:37am, Friday, 05'th Aug 2022
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Andrew Faughnan - Senior Director, IR Bradley Campbell - CEO, President & Direc
Amicus Therapeutics (FOLD) Reports Q2 Loss, Lags Revenue Estimates
12:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 8.70% and 5.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
11:00am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7%
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
11:50am, Wednesday, 03'rd Aug 2022 Benzinga
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.
Eargo, Inc. (NASDAQ: EAR) shares rose 148% to $1.74 in pre-ma
PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
10:17am, Wednesday, 03'rd Aug 2022 Benzinga
PayPal Holdings, Inc. (NASDAQ: PYPL) rose 12% to $100.35 in pre-market trading after the company reported better-than-expected Q2 results and raised FY22 EPS guidance.
Faraday Future Intelligent Elec
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
02:02pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
